Taglich Brothers Initiates Coverage On Ocean Biomedical with Speculative Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Taglich Brothers analyst Howard Halpern initiates coverage on Ocean Biomedical (NASDAQ:OCEA) with a Speculative Buy rating and announces a price target of $20.
May 31, 2023 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocean Biomedical (NASDAQ:OCEA) receives a Speculative Buy rating from Taglich Brothers analyst Howard Halpern with a price target of $20.
The initiation of coverage by Taglich Brothers with a Speculative Buy rating and a price target of $20 indicates a positive outlook for Ocean Biomedical's stock. This news is likely to attract investors' attention and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100